Metraipolis › archive › dc_b59cc54affdc

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system — Europe PMC PMID:40492137

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40492137
DOI: 10.3389/fphar.2025.1518258
License (as archived): solo-consultazione
Archived: 2026-10-08T01:23:38.714Z
SHA-256 of the archived text: 5e8169011c68090f69343e055d859354a82d41cfa2e810e7d467abb870f61bb9
Stable URL of this page: https://metraipolis.com/documento/dc_b59cc54affdc

How to cite

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system — Europe PMC PMID:40492137 — Europe PMC (en), https://europepmc.org/article/MED/40492137 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b59cc54affdc (Metraipolis archive dc_b59cc54affdc, sha256 5e8169011c68090f69343e055d859354a82d41cfa2e810e7d467abb870f61bb9)

BibTeX

@misc{dcb59cc54affdc,
  title = {Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system — Europe PMC PMID:40492137},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40492137},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b59cc54affdc; sha256 5e8169011c68090f69343e055d859354a82d41cfa2e810e7d467abb870f61bb9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40492137. Agents can read the archived copy with the MCP tool read_document.